Milestone Pharmaceuticals
6100 Royalmount Avenue
Montreal
Quebec
H4P 2R2
Canada
Tel: 514-496-3220
Fax: 514-496-3219
Website: http://www.milestonepharma.com/
Email: info@milestonepharma.com
113 articles about Milestone Pharmaceuticals
-
Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
5/17/2022
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto , President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.
-
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
5/12/2022
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2022, and provided a clinical and corporate update.
-
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
4/30/2022
Milestone Pharmaceuticals Inc. announced data from NODE-302, its Phase 3 open-label extension study of etripamil nasal spray, the Company's novel, investigational, calcium channel blocker in patients with paroxysmal supraventricular tachycardia.
-
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/15/2022
Milestone Pharmaceuticals Inc. today announced that Milestone's Compensation Committee granted one new employee 65,000 incentive stock options at a per share exercise price of $6.85.
-
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
4/14/2022
Milestone Pharmaceuticals Inc. today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Thursday, April 21, 2022 at 1:00 p.m. ET.
-
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update
3/24/2022
Milestone Pharmaceuticals Inc. today reported financial results for the fourth quarter and year ended December 31, 2021.
-
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - Mar 01, 2022
3/1/2022
Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that members of management will present at the following investor conferences.
-
Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer
2/16/2022
Milestone Pharmaceuticals Inc. today announced the appointment of David Bharucha , M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022.
-
Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
1/4/2022
Milestone Pharmaceuticals Inc. announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference being held on January 10-13, 2022.
-
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
11/15/2021
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), today announced new data from a post-hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the Company's novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).
-
Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
11/12/2021
Milestone Pharmaceuticals Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update.
-
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
-
Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
9/22/2021
Milestone Pharmaceuticals Inc. today announced that Amit Hasija, Chief Financial Officer and Executive Vice President of Corporate Development, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 10:00 a.m. ET.
-
Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
9/7/2021
Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021.
-
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
8/11/2021
Milestone Pharmaceuticals Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a clinical and corporate update.
-
Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference - May 26, 2021
5/26/2021
Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 4:00 PM ET.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
5/17/2021
Milestone Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update.
-
Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21
5/17/2021
Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial
-
Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
5/17/2021
Milestone Pharmaceuticals Inc. announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia and additional cardiovascular conditions in Greater China.